Ustekinumab
- Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study. Loeff et al., J Invest Dermatol. 2020 Nov;140(11):2129-2137. doi: 10.1016/j.jid.2020.03.957. Epub 2020 Apr 10.
- Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study. Pan et al., Clin Transl Sci. 2020 Mar;13(2):400-409. doi: 10.1111/cts.12725. Epub 2020 Jan 29. PMID: 31995663; PMCID: PMC7070790.
- Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis. Tsakok et al., JAMA Dermatol. 2019 Nov 1;155(11):1235-1243. doi: 10.1001/jamadermatol.2019.1783. PMID: 31532460; PMCID: PMC6751771.
- Subcutaneous rather than intravenous ustekinumab induction is associated with comparable circulating drug levels and early clinical response: a pilot study. Rowan et al., Aliment Pharmacol Ther. 2018 Aug;48(3):333-339. doi: 10.1111/apt.14834. Epub 2018 Jun 19. PMID: 29920697.
- The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting. Menting et al., Br J Dermatol. 2015 Sep;173(3):855-7. doi: 10.1111/bjd.13834. Epub 2015 Aug 2.
